ACER - Earnings announcements

Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in capital efficient structure Zevra to assume commercialization efforts of OLPRUVA™, recently approved for the treatment of urea cycle disorders (UCDs) FDA-approved commercial asset expected to increase and diversify Zevra's revenues OLPRUVA™ commercial operations provide Zevra scale and cost synergies to complement the potential launch of arimoclomol Adds EDSIVO™, a Phase 3 program for vascular Ehlers-Danlos Syndrome (vEDS), to Zevra's rare disease clinical pipeline Zevra to discuss details during conference call today, at 8:30 a.m. ET CELEBRATION, F

Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter as independent directorsCompleted four transactions from December 2021 through March 2022, deploying $38.5 millionReceived a $10.7 million cash payment from B&D Dental to successfully resolve long-running non-accrual position. Loan carried at $8.3 millionIn December 2021, subsidiary Enteris received a $5.0 million milestone payment from Cara Therapeutics with SWK retaining $3.0 millionEnteris currently advancing six partner feasibility studiesFinance Receivables Segment Update As of December 31